Directors and Management
Dr Andrew Kelly
Dr Kelly is Executive Director and Co-Founder of BioPacific Partners, a biotech investment and consulting firm focused on providing new product development services to many of the world’s largest pharmaceutical and consumer health companies. He has a PhD with management training and is broadly experienced and networked across the Australian biotech scene. His 35-year career spans the full spectrum of discovery science through to commercial success, focusing in equal measures on research, commercialisation and investment.
Starting with a Bachelor of Veterinary Science degree in the late 1970s, Dr Kelly engaged in life science research and development in Australia and Canada, attaining Master’s and PhD degrees, during the 1980s. He then led three separate research institutes – two in Australia and one in New Zealand, between 1992 and 2002. Following that period, Dr Kelly led new product development for Ag Research a large New Zealand research and development organisation, where he was also responsible for deep engagement with start-ups and fund-raising.
In 2005, Dr Kelly co-founded BioPacific Ventures, the first specialist venture fund focused across the spectrum of health, food and agriculture in Australia, which he led for 10 years. In 2014 he co-founded BioPacific Partners, partnering with some of the largest global companies investing and engaging with Australian innovation.
Dr Kelly is currently Executive director of BioPacific Partners Ltd (NZ), BioPacific Investments Ltd (NZ) and BioPacific Partners Pty Ltd (Australia) and has previously been Director of Focus Genetics Ltd (NZ), Horizon Science Ltd (AU), BioPacific Ventures Ltd (NZ), Anzamune Ltd (NZ), CMP Therapeutics Ltd (UK), Wool Equities (NZX listed), Encoate Ltd (NZ), Cleveland Biosensors Ltd (AU), InnerVision Ltd (NZ), Ultrafine Merino company Ltd (NZ), Velvet Antler Research New Zealand Ltd (NZ).
Dr Kelly will be an independent director. He will join the Board of the Company as a final stage before Completion of the Acquisition.
MBA, B.Tech (Mech) Post Grad Dip IT
Mr Yoshida is the founder and CEO of South Pacific Elixirs Pte Ltd (SPE Singapore). Mr Yoshida was born and raised in the Fiji Islands. He is extremely passionate about kava and understands its benefits first hand, having his first kava ceremony 30 years ago.
As the former co-founder and Managing Director of Styrotex (Asia Pacific) Sdn Bhd, Zane successfully commercialised and co-patented innovative technology in the plastics industry. He established a joint venture with a Malaysian public company and set-up companies in Shanghai and Suzhou through joint ventures and strategic acquisitions to manufacture products for supply to multinational electronics companies throughout China. Zane also established strategic partnerships in Thailand and South Korea via licence agreements, and distribution partnerships in Singapore and India.
He holds a Bachelor’s degree in Mechanical Technology, a Post Graduate Diploma in IT and a Master’s Degree in Business Administration (2002) from the Queensland University of Technology in Australia.
The Board considers that Mr Yoshida will not be an independent director. Mr Yoshida will join the Board of the Company upon completion of the Acquisition.
Adjunct Professor Stephen Copplin
B.Bus (Accountancy) FCPA, FAICD
Mr Copplin has been a Director of SPE Singapore since early in its inception and has worked closely with Zane Yoshida to develop the business. Mr Copplin is a Fellow of the Australian Institute of Company Directors, a Fellow Certified Practicing Accountant, a former Fellow of the Taxation Institute of Australia. Stephen recently completed 17 years as an Adjunct Professor at the University of Queensland in the Business School and continues to be an Adjunct Professor in the IT and Electrical Engineering School.
His current board roles are Chair, Scarpar Holdings Limited (HK), Director and Chair Finance and Risk Committee Gallipoli Medicinal Research Foundation. His past roles have included Chair Briz 31 Ltd, Chair Insurance Finance Australia and New Zealand, Chair Sheldon College Foundation Limited, Director Helping Hands Childcare Network, Director and Chair Audit and Risk Committee Queensland Museum, Founder and Chair CFO Centre Pty Ltd. Mr Copplin is also an experienced Angel Investor, being a Founding member of the ABOL sponsored Sydney Angels and a Founder of Brisbane Angels.
The Board considers that Mr Copplin will not be an independent director. Mr Copplin will join the Board of the Company upon completion of the Acquisition.
MBA, FCPA, FGIA, FCIS, CPA (Canada), CMA (Canada), MAICD
Non-Executive Director and Company Secretary
Mr Stephenson has been involved in business development for over 30 years including approximately 24 years as Director, Chief Financial Officer and Company Secretary for various listed and unlisted entities in resources, manufacturing, wine, hotels and property. He has been involved in business acquisitions, mergers, initial public offerings, capital raisings, and business restructuring, as well as managing all areas of finance for companies.
Mr Stephenson is currently the Chairman of Auctus Alternative Investments Limited (ASX:AVC), a Non-Executive Director and Company Secretary of Strategic Minerals Corporation NL (ASX:SMC), Dragon Mountain Gold Limited (ASX: DMG), and Nickelore Limited (ASX: NIO), a Non-Executive Director of Doray Minerals Limited (ASX: DRM) and Blina Minerals NL (ASX: BDI), and Company Secretary of Bubs Australia Limited (ASX: BUB), Noble Metals Limited (ASX: NMM), and Holista Colltech Limited (ASX: HCT).
Mr Stephenson has a Master of Business Administration from Heriot-Watt University, is a Fellow of Certified Practicing Accountants of Australia, a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Institute of Secretaries and Administrators, a Chartered Professional Accountant (Canada), a Certified Management Accountant (Canada), and a is a Member of the Australian Institute of Company Directors.
The Board considers that Mr Stephenson is an independent director.